Let’s Transform
Transplant Medicine.
Together.

Achieving more through our shared commitment to transplant medicine

See our pipeline

Learn more about who we are at Veloxis

Click to expand transcript

Veloxis, an Asahi Kasei company

At Veloxis, our focus is developing new therapies and programs to help transplant healthcare providers and the patients they treat. Now part of a global network, Veloxis is reaching further and growing faster, enabling us to continue being who we are as a company: Agile, Efficient, Responsive. Veloxis is following through on our promise to transform the future of transplant. Let’s transform transplant medicine. Together.

We know what transplant means to patients, and we’re leading innovation to improve their experience

For patients, transplant is a life-changing procedure. But changes come with challenges. At Veloxis, our mission is to see and respond to the challenges along the transplant journey. Our focus is developing new therapies and programs to help transplant healthcare providers and the patients they treat.

Learn about us

As part of a global network, Veloxis is reaching further and growing faster

As an Asahi Kasei company, we are able to expand our presence as a partner in care and innovation in medicine. The support and structured framework we have as part of Asahi Kasei enables us to be who we are as a company: agile, efficient, and responsive.

Meet our leadership
briefcase
CAREERS AT VELOXIS

“Veloxis’s Human Resources Department prides itself in providing an exceptional workplace environment for all employees. We strive to maintain a dynamic and innovative workplace that embraces diversity and encourages professional development. Our employees are our top priority!”

Rita Mannella, Sr. Director, Human Resources

Grow your career with us

Keep up with our headlines to see what we’ve been working on

press release
Press release

2022-06-28

Veloxis Pharmaceuticals Announces Dosing of the First Patient by partner Xenikos in the Global Phase 3 Study Evaluating T-Guard® in Patients with Steroid-Refractory Acute Graft-Versus-Host Disease (SR-aGVHD)

Veloxis Pharmaceuticals, an Ashai Kasei company, today announced dosing of the first patient by its partner, Xenikos, in a global pivotal Phase 3 clinical study [NCT04934670] designed to evaluate T-Guard® versus ruxolitinib for the treatment of patients with Grade III or IV steroid-refractory acute graft-versus-host disease (SR-aGVHD) following allogeneic hematopoietic stem cell transplant (allo-HSCT).

Read more
press release
Press release

2022-05-18

Veloxis Pharmaceuticals Announces Dosing of the First Participant in a Phase I Study of VEL-101, a Novel Investigational Drug for Kidney Transplant Immunosuppression

Veloxis Pharmaceuticals, Inc., an Asahi Kasei company, today announced that the first participant has been dosed in a Phase 1 Study of VEL-101 [NCT05238493]. VEL-101 is a novel investigational maintenance immunosuppressive agent being developed for prevention of acute rejection in kidney transplant recipients.

Read more
press release
Press release

2022-03-28

Veloxis Pharmaceuticals, Inc. Initiates Phase 1 Study of ART-123 in the U.S. and Japan

CARY, N.C., U.S.A. (March 28, 2022) – Veloxis Pharmaceuticals, Inc., an Asahi Kasei company, today announced initiation of study drug dosing in ART-123.PN101, a phase 1 study designed primarily to assess the safety and tolerability of ART-123 (thrombomodulin alfa) in metastatic colorectal cancer patients receiving chemotherapy that includes Oxaliplatin. The ART-123.PN101 study is being conducted jointly with Asahi Kasei Pharma Corp. in the United States and Japan.

Read more